| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 |
| filingDate |
1994-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1997-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a4d32db4780c4f381e6da914358ec2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46fe260bc2adfd08190ad2bf0d4f2996
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a0bc2c88de9a7a89d3d8b98bd1606e4 |
| publicationDate |
1997-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5639619-A |
| titleOfInvention |
Screening assay for anti-HIV drugs using the Vpr gene |
| abstract |
The essential role of the Vpr protein of HIV in the progression of HIV infection is disclosed. Recognition of this role permits assay for potential drug candidates by virtue of their ability to interfere with the interaction of Vpr with its intracellular targets. Thus, cells that are modified to contain an expression system for the production of Vpr are cultured in the presence and absence of the drug candidate and the growth rates compared. The ability of a candidate to enhance the growth of a culture producing Vpr indicates its potential as an anti-AIDS therapeutic. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6984486-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2868841-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003219797-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0049038-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005103654-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005103654-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0219602-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0219602-A3 |
| priorityDate |
1994-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |